Steven Ferguson, OD
Optometrist · Dakota Dunes, SDNPI 1952309502
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,939 of the $5,757 with a category attached, or 68.4%. 17 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 32.9% of the total. Reporting peaked in 2019 at $1,590 and has fallen 58.3% since, to $664 in 2025. Among optometrist clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 115 payments — averaging $50.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$2K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$922
- Bausch & Lomb Americas Inc.$661
- Sight Sciences, Inc.$560
- Dompe US, Inc.$435
- Tarsus Pharmaceuticals, Inc.$393
- plus $891 from 11 others
Across 5 payments — averaging $23,900 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Johnson & Johnson Surgical Vision, Inc.$120K
What the payments were for
- Consulting fees$1,80031%
- Food & beverage$3,93968%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 3 | $1,894 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 25 | $922 |
| Bausch & Lomb Americas Inc. | 28 | $661 |
| Sight Sciences, Inc. | 5 | $560 |
| Dompe US, Inc. | 11 | $435 |
| Tarsus Pharmaceuticals, Inc. | 10 | $393 |
| AbbVie(2 entities) | 9 | $247 |
| Glaukos Corporation | 4 | $190 |
| Sun Pharmaceutical Industries Inc. | 5 | $79 |
| Mallinckrodt Hospital Products Inc. | 3 | $77 |
| Rxsight Inc | 1 | $77 |
| Alcon | 3 | $71 |
| Biotissue Holdings Inc. | 3 | $58 |
| Novartis | 2 | $35 |
| Johnson & Johnson Vision Care, Inc. | 1 | $24 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Coopervision Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- One Series Ultra IOL Delivery System$600
- ULTRA$329
- BTOD$219
- TearCare SmartLid$200
- TEARCARE(TM) (2.2) SYSTEM KIT$200
- TEARCARE SYSTEM$142
- TearCare$141
- ALDEN SCLERAL ZENLENS$126
- XDEMVY$124
- INFUSE$121
- BIOTRUE ONE DAY$110
- Oxervate$103
How this compares
$5,757 in reported general payments places this provider in the 95th percentile of 206 optometrist providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 17 | $31,052 |
| VyzultaLatanoprostene Bunod | 58 | $21,233 |
| RestasisCyclosporine | 18 | $19,898 |
| MieboPerfluorohexyloctane/Pf | 22 | $15,994 |
| LumiganBimatoprost | 42 | $14,435 |
| Restasis MultidoseCyclosporine | 13 | $8,254 |
| CombiganBrimonidine Tartrate/Timolol | 18 | $4,638 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 32 | $4,071 |
| Lotemax SmLoteprednol Etabonate | 16 | $4,000 |
| AlrexLoteprednol Etabonate | 13 | $3,823 |
| Loteprednol Etabonate | 36 | $3,631 |
| Travoprost | 16 | $2,254 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 66 | $2,206 |
| Latanoprost | 170 | $876 |
| Doxycycline Hyclate | 36 | $831 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Restasis Multidose, Combigan | $247 | $47,22591 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Miebo | $661 | $37,22780 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $393 | $31,05217 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Alrex, Loteprednol Etabonate | $922 | $11,45465 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 206 optometrist providers in South Dakota.
Other optometrist in Dakota Dunes
- Justin SchweitzerSioux Falls$753K
- Mitchel IbachSioux Falls$395K
- Jason SchmitSioux Falls$79K
- Darren DohmanAberdeen$22K
- Jeffery SaylerSioux Falls$8K
- Jerika KirwanWagner$6K
- Kayla KarpukSioux Falls$6K
- Travis LehrSioux Falls$5K
- Matthew ClarkeSioux Falls$5K
- Ryan HaiarSioux Falls$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.